Cargando…

Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases

(1) Background: there are few studies on the inflammation of unknown origin (IUO). We sought to determine the etiologies and prognosis of IUO, as well as the contribution of complementary examinations. (2) Methods: this retrospective study analyzed patients meeting the Vanderschueren’s criteria in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Béra, Suzanne, Jamilloux, Yvan, Gerfaud-Valentin, Mathieu, Durupt, Stéphane, Nove-Josserand, Raphaèle, Lega, Jean-Christophe, Durieu, Isabelle, Hot, Arnaud, Sève, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745449/
https://www.ncbi.nlm.nih.gov/pubmed/35011773
http://dx.doi.org/10.3390/jcm11010032
_version_ 1784630347992924160
author Béra, Suzanne
Jamilloux, Yvan
Gerfaud-Valentin, Mathieu
Durupt, Stéphane
Nove-Josserand, Raphaèle
Lega, Jean-Christophe
Durieu, Isabelle
Hot, Arnaud
Sève, Pascal
author_facet Béra, Suzanne
Jamilloux, Yvan
Gerfaud-Valentin, Mathieu
Durupt, Stéphane
Nove-Josserand, Raphaèle
Lega, Jean-Christophe
Durieu, Isabelle
Hot, Arnaud
Sève, Pascal
author_sort Béra, Suzanne
collection PubMed
description (1) Background: there are few studies on the inflammation of unknown origin (IUO). We sought to determine the etiologies and prognosis of IUO, as well as the contribution of complementary examinations. (2) Methods: this retrospective study analyzed patients meeting the Vanderschueren’s criteria in the Hospices Civils de Lyon from 2005 to 2020. (3) Results: a total of 57 patients (mean age: 67 years; interquartile range: 55–79) were included. Final diagnoses were made for 26 (46%) patients. Non-infectious inflammatory diseases were the most common diagnoses (13/26, 50%), followed by neoplasms (10/26, 38%; 8/10 hematological malignancies), infections (2/26, 8%), and miscellaneous causes (1/26, 4%). Moreover, 18-FDG-PET/CT was contributory in 12/42 cases. Anti-neutrophil cytoplasmic antibodies, serology, temporal biopsies, and bone marrow aspirates were contributory in 3/41, 1/57, 5/23, and 3/19 cases, respectively. At last follow-up (mean follow-up duration: 48 months), 8/31 undiagnosed patients were cured (five received an empirical treatment), and 5/31 died (one death was related to the empirical treatment). (4) Conclusion: more than half of the IUO remained undiagnosed. Non-infectious inflammatory diseases and hematological malignancies were the most common etiologies. Moreover, 18-FDG-PET/CT had the highest diagnostic value. Most IUO without final diagnosis persisted. The role of empirical treatments remains to be explored.
format Online
Article
Text
id pubmed-8745449
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87454492022-01-11 Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases Béra, Suzanne Jamilloux, Yvan Gerfaud-Valentin, Mathieu Durupt, Stéphane Nove-Josserand, Raphaèle Lega, Jean-Christophe Durieu, Isabelle Hot, Arnaud Sève, Pascal J Clin Med Article (1) Background: there are few studies on the inflammation of unknown origin (IUO). We sought to determine the etiologies and prognosis of IUO, as well as the contribution of complementary examinations. (2) Methods: this retrospective study analyzed patients meeting the Vanderschueren’s criteria in the Hospices Civils de Lyon from 2005 to 2020. (3) Results: a total of 57 patients (mean age: 67 years; interquartile range: 55–79) were included. Final diagnoses were made for 26 (46%) patients. Non-infectious inflammatory diseases were the most common diagnoses (13/26, 50%), followed by neoplasms (10/26, 38%; 8/10 hematological malignancies), infections (2/26, 8%), and miscellaneous causes (1/26, 4%). Moreover, 18-FDG-PET/CT was contributory in 12/42 cases. Anti-neutrophil cytoplasmic antibodies, serology, temporal biopsies, and bone marrow aspirates were contributory in 3/41, 1/57, 5/23, and 3/19 cases, respectively. At last follow-up (mean follow-up duration: 48 months), 8/31 undiagnosed patients were cured (five received an empirical treatment), and 5/31 died (one death was related to the empirical treatment). (4) Conclusion: more than half of the IUO remained undiagnosed. Non-infectious inflammatory diseases and hematological malignancies were the most common etiologies. Moreover, 18-FDG-PET/CT had the highest diagnostic value. Most IUO without final diagnosis persisted. The role of empirical treatments remains to be explored. MDPI 2021-12-22 /pmc/articles/PMC8745449/ /pubmed/35011773 http://dx.doi.org/10.3390/jcm11010032 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Béra, Suzanne
Jamilloux, Yvan
Gerfaud-Valentin, Mathieu
Durupt, Stéphane
Nove-Josserand, Raphaèle
Lega, Jean-Christophe
Durieu, Isabelle
Hot, Arnaud
Sève, Pascal
Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title_full Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title_fullStr Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title_full_unstemmed Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title_short Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases
title_sort inflammation of unknown origin: evaluation and prognosis of 57 cases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745449/
https://www.ncbi.nlm.nih.gov/pubmed/35011773
http://dx.doi.org/10.3390/jcm11010032
work_keys_str_mv AT berasuzanne inflammationofunknownoriginevaluationandprognosisof57cases
AT jamillouxyvan inflammationofunknownoriginevaluationandprognosisof57cases
AT gerfaudvalentinmathieu inflammationofunknownoriginevaluationandprognosisof57cases
AT duruptstephane inflammationofunknownoriginevaluationandprognosisof57cases
AT novejosserandraphaele inflammationofunknownoriginevaluationandprognosisof57cases
AT legajeanchristophe inflammationofunknownoriginevaluationandprognosisof57cases
AT durieuisabelle inflammationofunknownoriginevaluationandprognosisof57cases
AT hotarnaud inflammationofunknownoriginevaluationandprognosisof57cases
AT sevepascal inflammationofunknownoriginevaluationandprognosisof57cases